Legal
Key facts
Hagens Berman says a securities class action lawsuit has been filed involving Regeneron Pharmaceuticals, Inc. (NASDAQ:…
Key facts
The lawsuit concerns Regeneron's Phase 3 clinical trial of Fianlimab in combination with Libtayo for first-line…
Key facts
The study's primary endpoint was progression-free survival (PFS)
Atlas Watchline
Hagens Berman says a securities class action has been filed against Regeneron Pharmaceuticals over disclosures tied…